A detailed history of Royal Bank Of Canada transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,242 shares of FULC stock, worth $28,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,242
Previous 5,944 5.01%
Holding current value
$28,401
Previous $36,000 38.89%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.18 - $9.74 $947 - $2,902
298 Added 5.01%
6,242 $22,000
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $35,497 - $55,264
5,936 Added 74200.0%
5,944 $36,000
Q1 2024

Nov 05, 2024

SELL
$6.7 - $12.0 $39,771 - $71,232
-5,936 Reduced 99.87%
8 $0
Q4 2023

Feb 14, 2024

SELL
$3.18 - $6.86 $6 - $13
-2 Reduced 20.0%
8 $0
Q2 2023

Aug 14, 2023

SELL
$2.26 - $3.8 $6,517 - $10,959
-2,884 Reduced 99.65%
10 $0
Q1 2023

May 15, 2023

SELL
$2.83 - $13.99 $13,462 - $66,550
-4,757 Reduced 62.17%
2,894 $8,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $36,152 - $60,253
7,216 Added 1658.85%
7,651 $55,000
Q3 2022

Nov 14, 2022

BUY
$4.92 - $9.1 $1,156 - $2,138
235 Added 117.5%
435 $3,000
Q2 2022

Aug 15, 2022

SELL
$4.2 - $24.0 $6,283 - $35,904
-1,496 Reduced 88.21%
200 $1,000
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $28,754 - $68,277
-2,887 Reduced 62.99%
1,696 $40,000
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $18,802 - $38,194
1,343 Added 41.45%
4,583 $81,000
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $12,536 - $53,330
1,722 Added 113.44%
3,240 $91,000
Q2 2021

Aug 16, 2021

BUY
$8.09 - $12.0 $12,280 - $18,216
1,518 New
1,518 $16,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.